Freeze-Thaw Cycles: What Happens to a Peptide Solution
Freezing a solution feels like pausing it. Chemically it is closer to the opposite: the act of freezing concentrates everything that is not water into a shrinking liquid fraction, and that fraction is where the damage happens.
Cryoconcentration
Water crystallises first and crystallises pure. Solutes are excluded from the growing ice and forced into the liquid that remains, so as freezing progresses the unfrozen portion becomes steadily more concentrated — in peptide, in buffer salts, and in anything else present.
Concentration is the main driver of self-association, so a solution that is stable at its nominal concentration can pass through conditions several times more concentrated on its way to solid. Aggregation covers what happens when molecules are pushed together.
The pH shift nobody expects
Buffer components do not concentrate equally. Where one component of a buffer pair is less soluble than the other, it crystallises out first and the ratio between them changes — which means the pH of the unfrozen fraction moves.
Phosphate buffers are the well-documented case: sodium phosphate systems can shift by more than a pH unit during freezing as the dibasic form precipitates preferentially. A peptide chosen to sit comfortably at pH 7 can therefore experience conditions well away from that while freezing. Isoelectric point and pH-dependent solubility covers why that matters.
The interface
Ice formation creates a large ice-liquid surface, and peptides adsorb to it. Adsorption at an interface partially unfolds a molecule, exposing hydrophobic regions that were previously internal, and those regions then associate with each other.
This is the same mechanism that makes vigorous shaking harmful, acting at a different kind of surface. It is also why rapid freezing is generally gentler than slow freezing: less time spent traversing the partially frozen state, and smaller crystals with less cumulative damage per cycle.
Why the effect is cumulative
Each cycle contributes its own increment of aggregation and its own opportunity for chemical change during the thaw, when the material is briefly concentrated, warm and liquid at once. Damage does not reverse on thawing, so five cycles is materially different from one.
This is the practical reason aliquoting is standard rather than fussy: dividing a stock into single-use portions means the material a given experiment uses has been through exactly one cycle. Aliquoting and vial entry covers the wider practice, which also limits moisture and oxygen exposure.
What thawing does
Thawing reverses the phase change, not the chemistry. Aggregates formed during freezing may partially redissolve, and covalent changes — deamidation, oxidation, disulfide exchange — do not reverse at all. Light, oxygen and temperature covers those routes, and disulfide bonds and scrambling covers the one specific to cysteine-containing sequences.
Lyophilised material sidesteps all of this, which is why peptides are supplied dry rather than in solution. Lyophilisation and the cake in the vial covers the dry state.
All material is supplied for laboratory research use only. It is not a drug, not a supplement, and not for use in humans or animals.
